Ardelyx Awaiting Next Steps From FDA To Resubmit NDA For Tenapanor For Hyperphosphatemia

Biopharmaceutical company Ardelyx, Inc. (ARDX) announced Wednesday that the company has met with the U.S. Food and Drug Administration (FDA) in a Type A meeting, but was not provided sufficient clarity on what constitutes "clinical relevance of the magnitude of treatment effect" and continues to await additional information regarding the path forward for the company's New Drug Application (NDA) for tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.

The company said it continues to be extremely disappointed and surprised by the lack of clarity from the FDA on the next steps to resubmit the NDA even after they have conducted the requisite registration studies, which met all primary and key secondary endpoints with no safety or other identified issues.

The company has made the extremely difficult decision to implement a restructuring plan that includes a significant reduction in operating costs and 65% of workforce to preserve cash resources and extend cash runway. It retained only the key employees needed to continue to support the regulatory process and work to achieve the goal to gain approval for tenapanor for hyperphosphatemia.

The restructuring plan is expected to be completed in December 2021. The company estimates that it will incur aggregate restructuring charges of approximately $2.3 million, which will be recorded primarily in the fourth quarter 2021, related to severance payments and other employee-related costs.

In July 2021, Ardelyx announced that it had received a complete response letter (CRL) from the FDA regarding the company's NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the fourth quarter on Friday, Colgate-Palmolive Co. (CL) initiated its earnings and sales growth guidance for the full-year 2022. For fiscal 2022, the company now expects earnings per share to grow in double-digit percentage and adjusted earnings per share growth... Caterpillar Inc. (CAT), a manufacturer of mining and construction equipment, reported Friday that fourth-quarter net income more than doubled to $2.12 billion or $3.91 per share from $780 million or $1.42 per share in the prior-year quarter. Excluding special items, adjusted net income for the quarter... United Airlines has opened its flight training school, United Aviate Academy, to bring out new pilots with a view to mainly empower women and people of color. The institute's first class of students is 80 percent women or people of color. This outpaces the airline's earlier goal to train about 5,000 new pilots at the school by 2030 with at least half being women or people of color.
Follow RTT